The prevalence of common obesity continues to increase despite very
serious efforts to prevent and treat it. Obesity leads to diabetes and cardiovascular
disease, which are still among the most important causes of death in developed
countries. Leptin replacement therapy has been successfully and effectively used in
patients with complete or partial leptin-deficient states. The discovery of leptin inspired
a great hope, but the expected success of leptin therapy has not been achieved for the
treatment of common obesity. After understanding leptin resistance as the basis of
common obesity, research has shifted to find leptin sensitizers that can be used in
humans. Despite extensive research, there is still no effective, widely used leptin
sensitier available for the treatment of common obesity. However, leptin sensitizers
offer promise as approved medications for the clinical treatment of common obesity.
The above-mentioned topics are explained in more detail in this chapter.
Keywords: 4-phenylbutyrate, Betulinic Acid, Celastrol, Congenital Leptin
Deficiency, Leptin, Leptin Replacement, Leptin Resistance, Leptin Sensitizer,
Lipodystrophy, Obesity, Oxytoxin, Tauroursodeoxycholic Acid, Withaferin.
